ConquerX

ConquerX, founded with a mission to revolutionize precision medicine, is a biotechnology company specializing in molecular profiling solutions. Their core vision is to enhance clinical trials through innovative technology. ConquerX's flagship product, EbeGen, is an electro-chemical biosensor that detects multiple molecular targets, including DNAs, RNAs, and miRNAs, simultaneously. This technology eliminates the need for sequencing and qPCR, offering a solution that is ten times more cost-effective than current methods. The company primarily focuses on the precision medicine market.

Notable figures affiliated with ConquerX include leading scientists and industry experts in biotechnology and precision medicine. The company has attracted significant interest from investors focused on healthcare innovation. Key achievements include the successful development and deployment of EbeGen in various clinical trials, demonstrating its efficacy and cost advantages. ConquerX's impact lies in its potential to significantly reduce the costs and time associated with molecular profiling, thereby accelerating advancements in precision medicine and improving patient outcomes.